Stifel Reiterates Buy Rating on Crinetics (CRNX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Crinetics (CRNX) PT Raised to $80 at Morgan Stanley
January 5, 2026 1:44 PM ESTMorgan Stanley analyst Jeffrey Hung raised the price target on Crinetics (NASDAQ: CRNX) to $80.00 (from $77.00) while maintaining a Overweight rating.
The analyst comments "We see atumelnant data continuing to demonstrate potential best-in-class efficacy, with no hepatic transaminase AEs. Nearterm, we expect investor... More
